8-K: IR-Med Secures $15 Million Equity Purchase Agreement with Williamsburg Venture Holdings

IR-Med, Inc. has entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, securing a commitment for up to $15 million in investment over a 24-month period.

Summary

• IR-Med, Inc. has entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, where the investor commits to invest up to $15 million over 24 months.
• The agreement, dated March 11, 2025, allows IR-Med to issue put notices to the investor for shares of common stock.
• The purchase price per share will be 90% of the market price, calculated as the average of the two lowest Volume-Weighted Average Prices (VWAP) for the five consecutive trading days before the clearing date.
• In consideration of the put rights, IR-Med will issue 1,000,000 shares of its common stock to the investor.
• The investor is restricted from acquiring more than 9.99% of IR-Med's outstanding common stock.
• A Registration Rights Agreement was also established, requiring IR-Med to register the common stock issuable under the Equity Purchase Agreement with the SEC.
• IR-Med must file a registration statement with the SEC by June 30, 2025, covering the resale of the put shares and commitment shares.
• The investor agrees to fund $500,000 pursuant to a Put Notice upon the Registration Statement being deemed effective by the SEC.

Sentiment

Score: 7

Explanation: The agreement provides IR-Med with access to capital, which is generally positive. However, the potential for dilution and the discounted purchase price temper the overall sentiment.

Positives

• IR-Med gains access to a potential $15 million in funding over 24 months.
• The structure of the agreement allows IR-Med to draw capital as needed.
• The agreement includes a Registration Rights Agreement, facilitating the resale of shares by the investor.
• The initial issuance of 1,000,000 shares provides immediate consideration to the investor.

Negatives

• The company is obligated to issue 1,000,000 shares of common stock to the investor.
• The company is obligated to file a registration statement with the SEC by June 30, 2025.
• The purchase price is discounted at 90% of the market price, potentially diluting shareholder value.

Risks

• The investor's ability to sell shares could be affected if the registration statement is not effective.
• The agreement's terms could lead to dilution of existing shareholders' equity.
• Market fluctuations could impact the price at which IR-Med can put shares to the investor.
• The investor may not purchase the full $15 million if certain conditions are not met.

Future Outlook

IR-Med anticipates utilizing the committed capital to further its business objectives, subject to market conditions and the effectiveness of the registration statement.

Industry Context

This type of agreement is common for small-cap companies seeking flexible access to capital. It allows them to avoid traditional equity offerings and draw funds as needed, but it can also lead to stock dilution.

Comparison to Industry Standards

• Similar equity purchase agreements are used by companies like Digital Ally, Inc. and Evofem Biosciences, Inc. to secure funding.
• The 90% of market price purchase price is a fairly standard discount for these types of agreements.
• The 24-month commitment period is also typical for these types of agreements.

Stakeholder Impact

• Shareholders may experience dilution if IR-Med issues a significant number of shares under the agreement.
• The company's financial stability could improve with access to additional capital.
• Employees may benefit from the company's ability to fund operations and growth.

Next Steps

• IR-Med must file a registration statement with the SEC by June 30, 2025.
• IR-Med will issue 1,000,000 commitment shares to the investor on the execution date.
• IR-Med will secure the listing of all Put Shares and Commitment Shares on the Principal Market.

Key Dates